Harae Dx Corp

Based in the US, Harae Dx Corp is a next-generation company specializing in advanced cancer diagnostics, utilizing proprietary AI technology to improve detection accuracy and efficiency for healthcare professionals. Harae Dx Corp is focused on providing innovative cancer diagnostic solutions. Founded in 2021, the company is headquartered in Pleasanton, US and has completed one funding deal. The most recent funding occurred on April 16, 2021, when Harae Dx Corp raised an undisclosed amount in a Seed round from investors SOSV and HAX.

HARAE DX specializes in advanced cancer diagnostics, leveraging its proprietary Unicorn AI technology to enhance the accuracy and efficiency of cancer detection. The company's core offerings focus on providing diagnostic tools that enable healthcare professionals to identify various types of cancer at earlier stages, thereby improving patient outcomes. These tools analyze complex data sets, incorporating machine learning and artificial intelligence to deliver actionable insights. HARAE DX’s client base includes hospitals, oncology clinics, and research institutions across the United States, Europe, and Asia, which rely on these innovative solutions to streamline diagnostic processes and improve patient care.

HARAE DX generates revenue through strategic partnerships with healthcare institutions and direct sales of its diagnostic solutions. The company operates on a B2B model, with clients purchasing subscriptions to its diagnostic platforms, essential for oncologists and medical professionals needing reliable cancer detection tools. These partnerships typically involve multi-year agreements that provide ongoing access to software updates and support, including training for healthcare providers to maximize the utility of HARAE DX's offerings. Specific pricing structures for these subscriptions and diagnostic services are tailored to the needs of individual clients.

Harae Dx Corp is focused on launching new products designed to enhance its diagnostic capabilities, although specific release dates have not been disclosed. The company aims to expand its market reach into Europe and Asia by 2023. The recent Seed funding raised in April 2021 will be utilized to support these growth initiatives, including product development and market entry strategies.